Shire revenues get shot in the arm

Shire, Britain’s third-largest drugmaker, yesterday reported 24 per cent third-quarter revenue growth, helped by robust demand for hyperactivity drugs and its medicines for rare diseases.

The company posted revenue of $1.09 billion (£677 million).Chief executive Angus Russell described it as a strong quarter while Morgan Stanley said the results demonstrated Shire’s “robust earnings power”.